nodes	percent_of_prediction	percent_of_DWPC	metapath
Fingolimod—CYP4F2—cardial valve—systemic scleroderma	0.203	0.498	CbGeAlD
Fingolimod—S1PR1—umbilical vein—systemic scleroderma	0.0424	0.104	CbGeAlD
Fingolimod—S1PR1—endothelium—systemic scleroderma	0.0201	0.0493	CbGeAlD
Fingolimod—S1PR1—blood vessel—systemic scleroderma	0.0185	0.0455	CbGeAlD
Fingolimod—S1PR5—skin of body—systemic scleroderma	0.0117	0.0287	CbGeAlD
Fingolimod—S1PR3—smooth muscle tissue—systemic scleroderma	0.00986	0.0242	CbGeAlD
Fingolimod—S1PR1—connective tissue—systemic scleroderma	0.00951	0.0233	CbGeAlD
Fingolimod—S1PR4—lung—systemic scleroderma	0.00932	0.0229	CbGeAlD
Fingolimod—CYP4F2—digestive system—systemic scleroderma	0.00878	0.0215	CbGeAlD
Fingolimod—S1PR1—smooth muscle tissue—systemic scleroderma	0.0087	0.0213	CbGeAlD
Fingolimod—SPHK1—smooth muscle tissue—systemic scleroderma	0.0086	0.0211	CbGeAlD
Fingolimod—SPHK1—skin of body—systemic scleroderma	0.00849	0.0208	CbGeAlD
Fingolimod—S1PR3—tendon—systemic scleroderma	0.00741	0.0182	CbGeAlD
Fingolimod—SPHK1—Beta3 integrin cell surface interactions—FBN1—systemic scleroderma	0.00714	0.123	CbGpPWpGaD
Fingolimod—CYP4F12—digestive system—systemic scleroderma	0.00653	0.016	CbGeAlD
Fingolimod—S1PR3—lung—systemic scleroderma	0.0065	0.016	CbGeAlD
Fingolimod—SPHK1—tendon—systemic scleroderma	0.00647	0.0159	CbGeAlD
Fingolimod—SPHK1—Beta3 integrin cell surface interactions—TGFBI—systemic scleroderma	0.00626	0.108	CbGpPWpGaD
Fingolimod—S1PR1—lung—systemic scleroderma	0.00573	0.0141	CbGeAlD
Fingolimod—SPHK1—lung—systemic scleroderma	0.00567	0.0139	CbGeAlD
Fingolimod—CYP4F12—lung—systemic scleroderma	0.00545	0.0134	CbGeAlD
Fingolimod—SPHK1—Beta3 integrin cell surface interactions—COL1A2—systemic scleroderma	0.00499	0.0859	CbGpPWpGaD
Fingolimod—SPHK1—Betamethasone—Mometasone—systemic scleroderma	0.00399	0.324	CbGdCrCtD
Fingolimod—SPHK1—Dexamethasone—Mometasone—systemic scleroderma	0.00399	0.324	CbGdCrCtD
Fingolimod—S1PR1—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.00232	0.0399	CbGpPWpGaD
Fingolimod—SPHK1—Dexamethasone—Prednisone—systemic scleroderma	0.00218	0.176	CbGdCrCtD
Fingolimod—SPHK1—Betamethasone—Prednisone—systemic scleroderma	0.00218	0.176	CbGdCrCtD
Fingolimod—SPHK1—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.00205	0.0353	CbGpPWpGaD
Fingolimod—S1PR1—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.00202	0.0347	CbGpPWpGaD
Fingolimod—SPHK1—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.00179	0.0307	CbGpPWpGaD
Fingolimod—Cardiac arrest—Mycophenolic acid—systemic scleroderma	0.00156	0.00299	CcSEcCtD
Fingolimod—Liver function test abnormal—Mycophenolic acid—systemic scleroderma	0.00151	0.0029	CcSEcCtD
Fingolimod—Cerebrovascular accident—Lisinopril—systemic scleroderma	0.00151	0.00289	CcSEcCtD
Fingolimod—Influenza—Leflunomide—systemic scleroderma	0.00148	0.00284	CcSEcCtD
Fingolimod—Leukopenia—Pentoxifylline—systemic scleroderma	0.00148	0.00284	CcSEcCtD
Fingolimod—Mediastinal disorder—Mometasone—systemic scleroderma	0.00148	0.00283	CcSEcCtD
Fingolimod—Aspartate aminotransferase increased—Mycophenolic acid—systemic scleroderma	0.00148	0.00283	CcSEcCtD
Fingolimod—Palpitations—Pentoxifylline—systemic scleroderma	0.00146	0.0028	CcSEcCtD
Fingolimod—Gastroenteritis—Mycophenolate mofetil—systemic scleroderma	0.00146	0.0028	CcSEcCtD
Fingolimod—Alanine aminotransferase increased—Mycophenolic acid—systemic scleroderma	0.00145	0.00277	CcSEcCtD
Fingolimod—Eye pain—Mycophenolate mofetil—systemic scleroderma	0.00143	0.00274	CcSEcCtD
Fingolimod—Hypertension—Pentoxifylline—systemic scleroderma	0.00143	0.00274	CcSEcCtD
Fingolimod—Bronchitis—Leflunomide—systemic scleroderma	0.00143	0.00274	CcSEcCtD
Fingolimod—Influenza—Mycophenolic acid—systemic scleroderma	0.00142	0.00271	CcSEcCtD
Fingolimod—Pneumonia—Azathioprine—systemic scleroderma	0.00141	0.0027	CcSEcCtD
Fingolimod—Cardiac arrest—Lisinopril—systemic scleroderma	0.0014	0.00269	CcSEcCtD
Fingolimod—Infestation NOS—Azathioprine—systemic scleroderma	0.0014	0.00269	CcSEcCtD
Fingolimod—Infestation—Azathioprine—systemic scleroderma	0.0014	0.00269	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.0014	0.00268	CcSEcCtD
Fingolimod—Back pain—Mometasone—systemic scleroderma	0.00138	0.00265	CcSEcCtD
Fingolimod—Bronchitis—Mycophenolic acid—systemic scleroderma	0.00136	0.00261	CcSEcCtD
Fingolimod—Weight decreased—Leflunomide—systemic scleroderma	0.00134	0.00257	CcSEcCtD
Fingolimod—Infection—Pentoxifylline—systemic scleroderma	0.00134	0.00257	CcSEcCtD
Fingolimod—Herpes zoster—Methotrexate—systemic scleroderma	0.00134	0.00257	CcSEcCtD
Fingolimod—Pneumonia—Leflunomide—systemic scleroderma	0.00133	0.00255	CcSEcCtD
Fingolimod—Infestation—Leflunomide—systemic scleroderma	0.00132	0.00254	CcSEcCtD
Fingolimod—Infestation NOS—Leflunomide—systemic scleroderma	0.00132	0.00254	CcSEcCtD
Fingolimod—Cerebrovascular accident—Mycophenolate mofetil—systemic scleroderma	0.00132	0.00253	CcSEcCtD
Fingolimod—Skin disorder—Pentoxifylline—systemic scleroderma	0.00131	0.00252	CcSEcCtD
Fingolimod—Weight decreased—Mycophenolic acid—systemic scleroderma	0.00128	0.00245	CcSEcCtD
Fingolimod—Influenza—Lisinopril—systemic scleroderma	0.00128	0.00244	CcSEcCtD
Fingolimod—Alopecia—Captopril—systemic scleroderma	0.00127	0.00244	CcSEcCtD
Fingolimod—Pneumonia—Mycophenolic acid—systemic scleroderma	0.00127	0.00243	CcSEcCtD
Fingolimod—Hypotension—Pentoxifylline—systemic scleroderma	0.00126	0.00242	CcSEcCtD
Fingolimod—Infestation NOS—Mycophenolic acid—systemic scleroderma	0.00126	0.00242	CcSEcCtD
Fingolimod—Infestation—Mycophenolic acid—systemic scleroderma	0.00126	0.00242	CcSEcCtD
Fingolimod—Cough—Mometasone—systemic scleroderma	0.00125	0.00239	CcSEcCtD
Fingolimod—Sinusitis—Leflunomide—systemic scleroderma	0.00124	0.00238	CcSEcCtD
Fingolimod—Cardiac arrest—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00236	CcSEcCtD
Fingolimod—Bronchitis—Lisinopril—systemic scleroderma	0.00123	0.00235	CcSEcCtD
Fingolimod—Dyspnoea—Pentoxifylline—systemic scleroderma	0.00121	0.00231	CcSEcCtD
Fingolimod—Liver function test abnormal—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00229	CcSEcCtD
Fingolimod—Sinusitis—Mycophenolic acid—systemic scleroderma	0.00118	0.00227	CcSEcCtD
Fingolimod—Vision blurred—Captopril—systemic scleroderma	0.00118	0.00227	CcSEcCtD
Fingolimod—Connective tissue disorder—Leflunomide—systemic scleroderma	0.00117	0.00224	CcSEcCtD
Fingolimod—Aspartate aminotransferase increased—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00223	CcSEcCtD
Fingolimod—Infection—Mometasone—systemic scleroderma	0.00116	0.00222	CcSEcCtD
Fingolimod—Weight decreased—Lisinopril—systemic scleroderma	0.00115	0.00221	CcSEcCtD
Fingolimod—Bradycardia—Mycophenolic acid—systemic scleroderma	0.00115	0.00221	CcSEcCtD
Fingolimod—Pneumonia—Lisinopril—systemic scleroderma	0.00114	0.00219	CcSEcCtD
Fingolimod—Alanine aminotransferase increased—Mycophenolate mofetil—systemic scleroderma	0.00114	0.00219	CcSEcCtD
Fingolimod—Depression—Lisinopril—systemic scleroderma	0.00113	0.00217	CcSEcCtD
Fingolimod—Mediastinal disorder—Azathioprine—systemic scleroderma	0.00113	0.00217	CcSEcCtD
Fingolimod—Influenza—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00214	CcSEcCtD
Fingolimod—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.00111	0.00213	CcSEcCtD
Fingolimod—Alopecia—Azathioprine—systemic scleroderma	0.00111	0.00213	CcSEcCtD
Fingolimod—Eye disorder—Leflunomide—systemic scleroderma	0.00111	0.00213	CcSEcCtD
Fingolimod—Palpitations—Captopril—systemic scleroderma	0.00111	0.00213	CcSEcCtD
Fingolimod—Cardiac disorder—Leflunomide—systemic scleroderma	0.0011	0.00211	CcSEcCtD
Fingolimod—CYP2E1—digestive system—systemic scleroderma	0.0011	0.0027	CbGeAlD
Fingolimod—Cough—Captopril—systemic scleroderma	0.0011	0.0021	CcSEcCtD
Fingolimod—Bronchitis—Mycophenolate mofetil—systemic scleroderma	0.00107	0.00206	CcSEcCtD
Fingolimod—Mediastinal disorder—Leflunomide—systemic scleroderma	0.00107	0.00205	CcSEcCtD
Fingolimod—Sinusitis—Lisinopril—systemic scleroderma	0.00107	0.00204	CcSEcCtD
Fingolimod—Hepatic enzyme increased—Methotrexate—systemic scleroderma	0.00107	0.00204	CcSEcCtD
Fingolimod—Eye disorder—Mycophenolic acid—systemic scleroderma	0.00106	0.00203	CcSEcCtD
Fingolimod—Cardiac disorder—Mycophenolic acid—systemic scleroderma	0.00105	0.00202	CcSEcCtD
Fingolimod—Alopecia—Leflunomide—systemic scleroderma	0.00105	0.00201	CcSEcCtD
Fingolimod—CYP2E1—tendon—systemic scleroderma	0.00105	0.00257	CbGeAlD
Fingolimod—Paraesthesia—Mometasone—systemic scleroderma	0.00105	0.00201	CcSEcCtD
Fingolimod—Mental disorder—Leflunomide—systemic scleroderma	0.00104	0.00199	CcSEcCtD
Fingolimod—Dyspnoea—Mometasone—systemic scleroderma	0.00104	0.00199	CcSEcCtD
Fingolimod—Bradycardia—Lisinopril—systemic scleroderma	0.00104	0.00199	CcSEcCtD
Fingolimod—Angiopathy—Mycophenolic acid—systemic scleroderma	0.00103	0.00197	CcSEcCtD
Fingolimod—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.00102	0.00196	CcSEcCtD
Fingolimod—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00194	CcSEcCtD
Fingolimod—Fatigue—Mometasone—systemic scleroderma	0.00101	0.00193	CcSEcCtD
Fingolimod—Pneumonia—Mycophenolate mofetil—systemic scleroderma	0.001	0.00192	CcSEcCtD
Fingolimod—Alopecia—Mycophenolic acid—systemic scleroderma	0.001	0.00192	CcSEcCtD
Fingolimod—Back pain—Leflunomide—systemic scleroderma	0.001	0.00192	CcSEcCtD
Fingolimod—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.000997	0.00191	CcSEcCtD
Fingolimod—Infestation—Mycophenolate mofetil—systemic scleroderma	0.000997	0.00191	CcSEcCtD
Fingolimod—Depression—Mycophenolate mofetil—systemic scleroderma	0.000994	0.0019	CcSEcCtD
Fingolimod—Mental disorder—Mycophenolic acid—systemic scleroderma	0.000993	0.0019	CcSEcCtD
Fingolimod—Leukopenia—Azathioprine—systemic scleroderma	0.000981	0.00188	CcSEcCtD
Fingolimod—Vision blurred—Leflunomide—systemic scleroderma	0.000975	0.00187	CcSEcCtD
Fingolimod—Asthenia—Pentoxifylline—systemic scleroderma	0.00097	0.00186	CcSEcCtD
Fingolimod—Hypotension—Captopril—systemic scleroderma	0.000957	0.00183	CcSEcCtD
Fingolimod—Pruritus—Pentoxifylline—systemic scleroderma	0.000956	0.00183	CcSEcCtD
Fingolimod—Back pain—Mycophenolic acid—systemic scleroderma	0.000955	0.00183	CcSEcCtD
Fingolimod—Sinusitis—Mycophenolate mofetil—systemic scleroderma	0.000935	0.00179	CcSEcCtD
Fingolimod—Vision blurred—Mycophenolic acid—systemic scleroderma	0.00093	0.00178	CcSEcCtD
Fingolimod—Angiopathy—Lisinopril—systemic scleroderma	0.000926	0.00177	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000926	0.00177	CcSEcCtD
Fingolimod—Leukopenia—Leflunomide—systemic scleroderma	0.000926	0.00177	CcSEcCtD
Fingolimod—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000925	0.00177	CcSEcCtD
Fingolimod—Mediastinal disorder—Lisinopril—systemic scleroderma	0.00092	0.00176	CcSEcCtD
Fingolimod—Paraesthesia—Captopril—systemic scleroderma	0.00092	0.00176	CcSEcCtD
Fingolimod—CYP2E1—lung—systemic scleroderma	0.000919	0.00226	CbGeAlD
Fingolimod—Palpitations—Leflunomide—systemic scleroderma	0.000914	0.00175	CcSEcCtD
Fingolimod—Dyspnoea—Captopril—systemic scleroderma	0.000913	0.00175	CcSEcCtD
Fingolimod—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.000911	0.00174	CcSEcCtD
Fingolimod—Cough—Leflunomide—systemic scleroderma	0.000903	0.00173	CcSEcCtD
Fingolimod—Alopecia—Lisinopril—systemic scleroderma	0.000902	0.00173	CcSEcCtD
Fingolimod—Mental disorder—Lisinopril—systemic scleroderma	0.000895	0.00171	CcSEcCtD
Fingolimod—Dizziness—Pentoxifylline—systemic scleroderma	0.000894	0.00171	CcSEcCtD
Fingolimod—Hypertension—Leflunomide—systemic scleroderma	0.000893	0.00171	CcSEcCtD
Fingolimod—Infection—Azathioprine—systemic scleroderma	0.000888	0.0017	CcSEcCtD
Fingolimod—CYP3A4—digestive system—systemic scleroderma	0.000886	0.00217	CbGeAlD
Fingolimod—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000883	0.00169	CcSEcCtD
Fingolimod—Fatigue—Captopril—systemic scleroderma	0.000883	0.00169	CcSEcCtD
Fingolimod—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000879	0.00168	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000875	0.00168	CcSEcCtD
Fingolimod—Palpitations—Mycophenolic acid—systemic scleroderma	0.000872	0.00167	CcSEcCtD
Fingolimod—CYP2D6—digestive system—systemic scleroderma	0.000872	0.00214	CbGeAlD
Fingolimod—Skin disorder—Azathioprine—systemic scleroderma	0.000868	0.00166	CcSEcCtD
Fingolimod—Cough—Mycophenolic acid—systemic scleroderma	0.000861	0.00165	CcSEcCtD
Fingolimod—Back pain—Lisinopril—systemic scleroderma	0.00086	0.00165	CcSEcCtD
Fingolimod—Hypertension—Mycophenolic acid—systemic scleroderma	0.000852	0.00163	CcSEcCtD
Fingolimod—Headache—Pentoxifylline—systemic scleroderma	0.000847	0.00162	CcSEcCtD
Fingolimod—Infection—Leflunomide—systemic scleroderma	0.000839	0.00161	CcSEcCtD
Fingolimod—Vision blurred—Lisinopril—systemic scleroderma	0.000838	0.0016	CcSEcCtD
Fingolimod—Asthenia—Mometasone—systemic scleroderma	0.000837	0.0016	CcSEcCtD
Fingolimod—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000836	0.0016	CcSEcCtD
Fingolimod—Hypotension—Azathioprine—systemic scleroderma	0.000835	0.0016	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000834	0.0016	CcSEcCtD
Fingolimod—Cardiac arrest—Prednisone—systemic scleroderma	0.000834	0.0016	CcSEcCtD
Fingolimod—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.00083	0.00159	CcSEcCtD
Fingolimod—Nervous system disorder—Leflunomide—systemic scleroderma	0.000828	0.00159	CcSEcCtD
Fingolimod—Pruritus—Mometasone—systemic scleroderma	0.000825	0.00158	CcSEcCtD
Fingolimod—Skin disorder—Leflunomide—systemic scleroderma	0.00082	0.00157	CcSEcCtD
Fingolimod—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000812	0.00156	CcSEcCtD
Fingolimod—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000806	0.00154	CcSEcCtD
Fingolimod—Infection—Mycophenolic acid—systemic scleroderma	0.0008	0.00153	CcSEcCtD
Fingolimod—Diarrhoea—Mometasone—systemic scleroderma	0.000798	0.00153	CcSEcCtD
Fingolimod—Leukopenia—Lisinopril—systemic scleroderma	0.000796	0.00152	CcSEcCtD
Fingolimod—SPHK1—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000794	0.0137	CbGpPWpGaD
Fingolimod—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000791	0.00151	CcSEcCtD
Fingolimod—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00079	0.00151	CcSEcCtD
Fingolimod—Hypotension—Leflunomide—systemic scleroderma	0.000789	0.00151	CcSEcCtD
Fingolimod—Palpitations—Lisinopril—systemic scleroderma	0.000786	0.0015	CcSEcCtD
Fingolimod—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000784	0.0015	CcSEcCtD
Fingolimod—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000782	0.0015	CcSEcCtD
Fingolimod—Cough—Lisinopril—systemic scleroderma	0.000776	0.00149	CcSEcCtD
Fingolimod—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000773	0.00148	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000772	0.00148	CcSEcCtD
Fingolimod—Paraesthesia—Leflunomide—systemic scleroderma	0.000758	0.00145	CcSEcCtD
Fingolimod—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000753	0.00144	CcSEcCtD
Fingolimod—Dyspnoea—Leflunomide—systemic scleroderma	0.000753	0.00144	CcSEcCtD
Fingolimod—Hypotension—Mycophenolic acid—systemic scleroderma	0.000753	0.00144	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000752	0.00144	CcSEcCtD
Fingolimod—SPHK1—Signaling by VEGF—NOS3—systemic scleroderma	0.000749	0.0129	CbGpPWpGaD
Fingolimod—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.000748	0.00143	CcSEcCtD
Fingolimod—CYP4F2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000736	0.0127	CbGpPWpGaD
Fingolimod—Asthenia—Captopril—systemic scleroderma	0.000735	0.00141	CcSEcCtD
Fingolimod—Headache—Mometasone—systemic scleroderma	0.000731	0.0014	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000729	0.0014	CcSEcCtD
Fingolimod—Fatigue—Leflunomide—systemic scleroderma	0.000728	0.00139	CcSEcCtD
Fingolimod—Pruritus—Captopril—systemic scleroderma	0.000725	0.00139	CcSEcCtD
Fingolimod—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000723	0.00139	CcSEcCtD
Fingolimod—Infection—Lisinopril—systemic scleroderma	0.000721	0.00138	CcSEcCtD
Fingolimod—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000718	0.00138	CcSEcCtD
Fingolimod—S1PR4—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000714	0.0123	CbGpPWpGaD
Fingolimod—Skin disorder—Lisinopril—systemic scleroderma	0.000705	0.00135	CcSEcCtD
Fingolimod—Diarrhoea—Captopril—systemic scleroderma	0.000701	0.00134	CcSEcCtD
Fingolimod—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000697	0.00134	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000695	0.00133	CcSEcCtD
Fingolimod—Fatigue—Mycophenolic acid—systemic scleroderma	0.000694	0.00133	CcSEcCtD
Fingolimod—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000688	0.00132	CcSEcCtD
Fingolimod—S1PR5—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000687	0.0118	CbGpPWpGaD
Fingolimod—S1PR3—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000687	0.0118	CbGpPWpGaD
Fingolimod—Weight decreased—Prednisone—systemic scleroderma	0.000685	0.00131	CcSEcCtD
Fingolimod—Cough—Mycophenolate mofetil—systemic scleroderma	0.00068	0.0013	CcSEcCtD
Fingolimod—Hypotension—Lisinopril—systemic scleroderma	0.000678	0.0013	CcSEcCtD
Fingolimod—Dizziness—Captopril—systemic scleroderma	0.000677	0.0013	CcSEcCtD
Fingolimod—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000676	0.0013	CcSEcCtD
Fingolimod—Depression—Prednisone—systemic scleroderma	0.000674	0.00129	CcSEcCtD
Fingolimod—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000672	0.00129	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000658	0.00126	CcSEcCtD
Fingolimod—Paraesthesia—Lisinopril—systemic scleroderma	0.000651	0.00125	CcSEcCtD
Fingolimod—Dyspnoea—Lisinopril—systemic scleroderma	0.000647	0.00124	CcSEcCtD
Fingolimod—Headache—Captopril—systemic scleroderma	0.000642	0.00123	CcSEcCtD
Fingolimod—SPHK1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000632	0.0109	CbGpPWpGaD
Fingolimod—Infection—Mycophenolate mofetil—systemic scleroderma	0.000631	0.00121	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000626	0.0012	CcSEcCtD
Fingolimod—Fatigue—Lisinopril—systemic scleroderma	0.000625	0.0012	CcSEcCtD
Fingolimod—S1PR1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000624	0.0107	CbGpPWpGaD
Fingolimod—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000623	0.00119	CcSEcCtD
Fingolimod—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000617	0.00118	CcSEcCtD
Fingolimod—Bradycardia—Prednisone—systemic scleroderma	0.000617	0.00118	CcSEcCtD
Fingolimod—Diarrhoea—Azathioprine—systemic scleroderma	0.000612	0.00117	CcSEcCtD
Fingolimod—Asthenia—Leflunomide—systemic scleroderma	0.000606	0.00116	CcSEcCtD
Fingolimod—S1PR4—GPCR downstream signaling—RHOB—systemic scleroderma	0.000602	0.0104	CbGpPWpGaD
Fingolimod—Pruritus—Leflunomide—systemic scleroderma	0.000597	0.00114	CcSEcCtD
Fingolimod—Connective tissue disorder—Prednisone—systemic scleroderma	0.000596	0.00114	CcSEcCtD
Fingolimod—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000594	0.00114	CcSEcCtD
Fingolimod—Dizziness—Azathioprine—systemic scleroderma	0.000591	0.00113	CcSEcCtD
Fingolimod—S1PR5—GPCR downstream signaling—RHOB—systemic scleroderma	0.000579	0.00996	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—RHOB—systemic scleroderma	0.000579	0.00996	CbGpPWpGaD
Fingolimod—Asthenia—Mycophenolic acid—systemic scleroderma	0.000578	0.00111	CcSEcCtD
Fingolimod—Diarrhoea—Leflunomide—systemic scleroderma	0.000578	0.00111	CcSEcCtD
Fingolimod—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000571	0.00109	CcSEcCtD
Fingolimod—Pruritus—Mycophenolic acid—systemic scleroderma	0.00057	0.00109	CcSEcCtD
Fingolimod—Pneumonia—Methotrexate—systemic scleroderma	0.000568	0.00109	CcSEcCtD
Fingolimod—Eye disorder—Prednisone—systemic scleroderma	0.000567	0.00109	CcSEcCtD
Fingolimod—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000567	0.00109	CcSEcCtD
Fingolimod—Infestation NOS—Methotrexate—systemic scleroderma	0.000565	0.00108	CcSEcCtD
Fingolimod—Infestation—Methotrexate—systemic scleroderma	0.000565	0.00108	CcSEcCtD
Fingolimod—Depression—Methotrexate—systemic scleroderma	0.000563	0.00108	CcSEcCtD
Fingolimod—Headache—Azathioprine—systemic scleroderma	0.00056	0.00107	CcSEcCtD
Fingolimod—Dizziness—Leflunomide—systemic scleroderma	0.000558	0.00107	CcSEcCtD
Fingolimod—CYP4F2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000558	0.0096	CbGpPWpGaD
Fingolimod—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000551	0.00106	CcSEcCtD
Fingolimod—Angiopathy—Prednisone—systemic scleroderma	0.00055	0.00105	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000549	0.00105	CcSEcCtD
Fingolimod—S1PR4—Signaling by GPCR—RHOB—systemic scleroderma	0.000546	0.0094	CbGpPWpGaD
Fingolimod—S1PR4—GPCR ligand binding—EDN1—systemic scleroderma	0.000543	0.00935	CbGpPWpGaD
Fingolimod—Alopecia—Prednisone—systemic scleroderma	0.000536	0.00103	CcSEcCtD
Fingolimod—Dizziness—Mycophenolic acid—systemic scleroderma	0.000533	0.00102	CcSEcCtD
Fingolimod—Mental disorder—Prednisone—systemic scleroderma	0.000531	0.00102	CcSEcCtD
Fingolimod—Headache—Leflunomide—systemic scleroderma	0.000529	0.00101	CcSEcCtD
Fingolimod—S1PR3—Signaling by GPCR—RHOB—systemic scleroderma	0.000526	0.00905	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—RHOB—systemic scleroderma	0.000526	0.00905	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000526	0.00905	CbGpPWpGaD
Fingolimod—S1PR3—GPCR ligand binding—EDN1—systemic scleroderma	0.000523	0.009	CbGpPWpGaD
Fingolimod—S1PR5—GPCR ligand binding—EDN1—systemic scleroderma	0.000523	0.009	CbGpPWpGaD
Fingolimod—Asthenia—Lisinopril—systemic scleroderma	0.00052	0.000997	CcSEcCtD
Fingolimod—Pruritus—Lisinopril—systemic scleroderma	0.000513	0.000983	CcSEcCtD
Fingolimod—Headache—Mycophenolic acid—systemic scleroderma	0.000505	0.000967	CcSEcCtD
Fingolimod—Vision blurred—Prednisone—systemic scleroderma	0.000498	0.000953	CcSEcCtD
Fingolimod—Diarrhoea—Lisinopril—systemic scleroderma	0.000496	0.000951	CcSEcCtD
Fingolimod—S1PR4—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000488	0.0084	CbGpPWpGaD
Fingolimod—Dizziness—Lisinopril—systemic scleroderma	0.00048	0.000919	CcSEcCtD
Fingolimod—SPHK1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000479	0.00824	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—RHOB—systemic scleroderma	0.000477	0.00822	CbGpPWpGaD
Fingolimod—S1PR1—GPCR ligand binding—EDN1—systemic scleroderma	0.000475	0.00817	CbGpPWpGaD
Fingolimod—Eye disorder—Methotrexate—systemic scleroderma	0.000474	0.000907	CcSEcCtD
Fingolimod—Cardiac disorder—Methotrexate—systemic scleroderma	0.00047	0.000901	CcSEcCtD
Fingolimod—S1PR5—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.00047	0.00808	CbGpPWpGaD
Fingolimod—S1PR3—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.00047	0.00808	CbGpPWpGaD
Fingolimod—Angiopathy—Methotrexate—systemic scleroderma	0.00046	0.000881	CcSEcCtD
Fingolimod—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000457	0.000875	CcSEcCtD
Fingolimod—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000456	0.000874	CcSEcCtD
Fingolimod—Hypertension—Prednisone—systemic scleroderma	0.000456	0.000873	CcSEcCtD
Fingolimod—Headache—Lisinopril—systemic scleroderma	0.000454	0.000871	CcSEcCtD
Fingolimod—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00045	0.000862	CcSEcCtD
Fingolimod—Alopecia—Methotrexate—systemic scleroderma	0.000448	0.000858	CcSEcCtD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000446	0.000855	CcSEcCtD
Fingolimod—Mental disorder—Methotrexate—systemic scleroderma	0.000444	0.000851	CcSEcCtD
Fingolimod—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000435	0.000833	CcSEcCtD
Fingolimod—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000431	0.00742	CbGpPWpGaD
Fingolimod—Infection—Prednisone—systemic scleroderma	0.000428	0.00082	CcSEcCtD
Fingolimod—Back pain—Methotrexate—systemic scleroderma	0.000427	0.000818	CcSEcCtD
Fingolimod—S1PR1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000426	0.00734	CbGpPWpGaD
Fingolimod—Nervous system disorder—Prednisone—systemic scleroderma	0.000423	0.000809	CcSEcCtD
Fingolimod—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00042	0.000805	CcSEcCtD
Fingolimod—Skin disorder—Prednisone—systemic scleroderma	0.000418	0.000802	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—SMAD7—systemic scleroderma	0.000417	0.00718	CbGpPWpGaD
Fingolimod—Vision blurred—Methotrexate—systemic scleroderma	0.000416	0.000797	CcSEcCtD
Fingolimod—S1PR5—Signaling Pathways—SMAD7—systemic scleroderma	0.000402	0.00691	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—SMAD7—systemic scleroderma	0.000402	0.00691	CbGpPWpGaD
Fingolimod—Headache—Mycophenolate mofetil—systemic scleroderma	0.000398	0.000763	CcSEcCtD
Fingolimod—Leukopenia—Methotrexate—systemic scleroderma	0.000395	0.000757	CcSEcCtD
Fingolimod—SPHK1—Metabolism of proteins—ACE—systemic scleroderma	0.000387	0.00666	CbGpPWpGaD
Fingolimod—Paraesthesia—Prednisone—systemic scleroderma	0.000387	0.000741	CcSEcCtD
Fingolimod—Cough—Methotrexate—systemic scleroderma	0.000385	0.000738	CcSEcCtD
Fingolimod—CYP4F12—Metabolism—HSPG2—systemic scleroderma	0.00038	0.00653	CbGpPWpGaD
Fingolimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000373	0.000715	CcSEcCtD
Fingolimod—S1PR4—GPCR ligand binding—CCL2—systemic scleroderma	0.000372	0.00639	CbGpPWpGaD
Fingolimod—Fatigue—Prednisone—systemic scleroderma	0.000371	0.000712	CcSEcCtD
Fingolimod—S1PR1—Signaling Pathways—SMAD7—systemic scleroderma	0.000365	0.00627	CbGpPWpGaD
Fingolimod—Infection—Methotrexate—systemic scleroderma	0.000358	0.000685	CcSEcCtD
Fingolimod—S1PR3—GPCR ligand binding—CCL2—systemic scleroderma	0.000358	0.00615	CbGpPWpGaD
Fingolimod—S1PR5—GPCR ligand binding—CCL2—systemic scleroderma	0.000358	0.00615	CbGpPWpGaD
Fingolimod—Nervous system disorder—Methotrexate—systemic scleroderma	0.000353	0.000677	CcSEcCtD
Fingolimod—Skin disorder—Methotrexate—systemic scleroderma	0.00035	0.00067	CcSEcCtD
Fingolimod—Hypotension—Methotrexate—systemic scleroderma	0.000336	0.000645	CcSEcCtD
Fingolimod—CYP4F2—Metabolism—HSPG2—systemic scleroderma	0.000328	0.00564	CbGpPWpGaD
Fingolimod—S1PR1—GPCR ligand binding—CCL2—systemic scleroderma	0.000325	0.00559	CbGpPWpGaD
Fingolimod—Paraesthesia—Methotrexate—systemic scleroderma	0.000323	0.000619	CcSEcCtD
Fingolimod—SPHK1—Signaling Pathways—SMAD7—systemic scleroderma	0.000323	0.00555	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—RHOB—systemic scleroderma	0.000323	0.00555	CbGpPWpGaD
Fingolimod—Dyspnoea—Methotrexate—systemic scleroderma	0.000321	0.000615	CcSEcCtD
Fingolimod—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000311	0.000596	CcSEcCtD
Fingolimod—S1PR3—Signaling Pathways—RHOB—systemic scleroderma	0.000311	0.00535	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—RHOB—systemic scleroderma	0.000311	0.00535	CbGpPWpGaD
Fingolimod—Fatigue—Methotrexate—systemic scleroderma	0.00031	0.000595	CcSEcCtD
Fingolimod—Asthenia—Prednisone—systemic scleroderma	0.000309	0.000592	CcSEcCtD
Fingolimod—S1PR4—GPCR downstream signaling—EDN1—systemic scleroderma	0.000307	0.00529	CbGpPWpGaD
Fingolimod—Pruritus—Prednisone—systemic scleroderma	0.000305	0.000584	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—HSPG2—systemic scleroderma	0.000304	0.00524	CbGpPWpGaD
Fingolimod—S1PR5—GPCR downstream signaling—EDN1—systemic scleroderma	0.000296	0.00509	CbGpPWpGaD
Fingolimod—S1PR3—GPCR downstream signaling—EDN1—systemic scleroderma	0.000296	0.00509	CbGpPWpGaD
Fingolimod—Diarrhoea—Prednisone—systemic scleroderma	0.000295	0.000565	CcSEcCtD
Fingolimod—S1PR4—Signaling Pathways—CSK—systemic scleroderma	0.000294	0.00506	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—HSPG2—systemic scleroderma	0.000293	0.00504	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—HSPG2—systemic scleroderma	0.000293	0.00504	CbGpPWpGaD
Fingolimod—CYP4F12—Metabolism—CTGF—systemic scleroderma	0.000288	0.00495	CbGpPWpGaD
Fingolimod—Dizziness—Prednisone—systemic scleroderma	0.000285	0.000546	CcSEcCtD
Fingolimod—S1PR5—Signaling Pathways—CSK—systemic scleroderma	0.000283	0.00487	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CSK—systemic scleroderma	0.000283	0.00487	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—RHOB—systemic scleroderma	0.000282	0.00485	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—HSPG2—systemic scleroderma	0.000282	0.00484	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—EDN1—systemic scleroderma	0.000279	0.0048	CbGpPWpGaD
Fingolimod—Headache—Prednisone—systemic scleroderma	0.00027	0.000517	CcSEcCtD
Fingolimod—S1PR3—Signaling by GPCR—EDN1—systemic scleroderma	0.000268	0.00462	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—EDN1—systemic scleroderma	0.000268	0.00462	CbGpPWpGaD
Fingolimod—S1PR1—GPCR downstream signaling—EDN1—systemic scleroderma	0.000268	0.00462	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—HSPG2—systemic scleroderma	0.000266	0.00458	CbGpPWpGaD
Fingolimod—Asthenia—Methotrexate—systemic scleroderma	0.000258	0.000495	CcSEcCtD
Fingolimod—S1PR1—Signaling Pathways—CSK—systemic scleroderma	0.000257	0.00442	CbGpPWpGaD
Fingolimod—Pruritus—Methotrexate—systemic scleroderma	0.000255	0.000488	CcSEcCtD
Fingolimod—SPHK1—Signaling Pathways—RHOB—systemic scleroderma	0.00025	0.0043	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of proteins—MMP1—systemic scleroderma	0.000249	0.00428	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism—CTGF—systemic scleroderma	0.000248	0.00427	CbGpPWpGaD
Fingolimod—Diarrhoea—Methotrexate—systemic scleroderma	0.000246	0.000472	CcSEcCtD
Fingolimod—S1PR1—Signaling by GPCR—EDN1—systemic scleroderma	0.000244	0.0042	CbGpPWpGaD
Fingolimod—Dizziness—Methotrexate—systemic scleroderma	0.000238	0.000456	CcSEcCtD
Fingolimod—SPHK1—Signaling Pathways—HSPG2—systemic scleroderma	0.000235	0.00405	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CSK—systemic scleroderma	0.000227	0.00391	CbGpPWpGaD
Fingolimod—Headache—Methotrexate—systemic scleroderma	0.000226	0.000432	CcSEcCtD
Fingolimod—SPHK1—Metabolism—CTGF—systemic scleroderma	0.000213	0.00367	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of proteins—CCL2—systemic scleroderma	0.000202	0.00348	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism of proteins—MMP2—systemic scleroderma	0.000192	0.00331	CbGpPWpGaD
Fingolimod—S1PR4—Signaling by GPCR—CCL2—systemic scleroderma	0.000191	0.00328	CbGpPWpGaD
Fingolimod—S1PR3—Signaling by GPCR—CCL2—systemic scleroderma	0.000184	0.00316	CbGpPWpGaD
Fingolimod—S1PR5—Signaling by GPCR—CCL2—systemic scleroderma	0.000184	0.00316	CbGpPWpGaD
Fingolimod—S1PR1—Signaling by GPCR—CCL2—systemic scleroderma	0.000167	0.00287	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—EDN1—systemic scleroderma	0.000165	0.00284	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—EDN1—systemic scleroderma	0.000159	0.00273	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—EDN1—systemic scleroderma	0.000159	0.00273	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—EDN1—systemic scleroderma	0.000144	0.00248	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—EDN1—systemic scleroderma	0.000127	0.00219	CbGpPWpGaD
Fingolimod—CYP4F12—Metabolism—NOS3—systemic scleroderma	0.000125	0.00215	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—CCL2—systemic scleroderma	0.000113	0.00194	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—CCL2—systemic scleroderma	0.000108	0.00187	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—CCL2—systemic scleroderma	0.000108	0.00187	CbGpPWpGaD
Fingolimod—CYP4F2—Metabolism—NOS3—systemic scleroderma	0.000108	0.00186	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—NOS3—systemic scleroderma	0.0001	0.00173	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—CCL2—systemic scleroderma	9.84e-05	0.00169	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—NOS3—systemic scleroderma	9.66e-05	0.00166	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—NOS3—systemic scleroderma	9.66e-05	0.00166	CbGpPWpGaD
Fingolimod—SPHK1—Metabolism—NOS3—systemic scleroderma	9.29e-05	0.0016	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—NOS3—systemic scleroderma	8.77e-05	0.00151	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—CCL2—systemic scleroderma	8.71e-05	0.0015	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—MMP9—systemic scleroderma	8.05e-05	0.00139	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—NOS3—systemic scleroderma	7.77e-05	0.00134	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—MMP9—systemic scleroderma	7.75e-05	0.00133	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—MMP9—systemic scleroderma	7.75e-05	0.00133	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—MMP9—systemic scleroderma	7.04e-05	0.00121	CbGpPWpGaD
Fingolimod—S1PR4—Signaling Pathways—TGFB1—systemic scleroderma	6.64e-05	0.00114	CbGpPWpGaD
Fingolimod—S1PR5—Signaling Pathways—TGFB1—systemic scleroderma	6.39e-05	0.0011	CbGpPWpGaD
Fingolimod—S1PR3—Signaling Pathways—TGFB1—systemic scleroderma	6.39e-05	0.0011	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—MMP9—systemic scleroderma	6.23e-05	0.00107	CbGpPWpGaD
Fingolimod—S1PR1—Signaling Pathways—TGFB1—systemic scleroderma	5.8e-05	0.000998	CbGpPWpGaD
Fingolimod—SPHK1—Signaling Pathways—TGFB1—systemic scleroderma	5.14e-05	0.000884	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—HSPG2—systemic scleroderma	4.62e-05	0.000795	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—CTGF—systemic scleroderma	3.5e-05	0.000603	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—HSPG2—systemic scleroderma	3.28e-05	0.000564	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—CTGF—systemic scleroderma	2.49e-05	0.000428	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—HSPG2—systemic scleroderma	2.14e-05	0.000369	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.63e-05	0.00028	CbGpPWpGaD
Fingolimod—CYP2E1—Metabolism—NOS3—systemic scleroderma	1.52e-05	0.000262	CbGpPWpGaD
Fingolimod—CYP2D6—Metabolism—NOS3—systemic scleroderma	1.08e-05	0.000186	CbGpPWpGaD
Fingolimod—CYP3A4—Metabolism—NOS3—systemic scleroderma	7.07e-06	0.000122	CbGpPWpGaD
